MK-677 Research for Muscle Wasting
An evidence-based overview of research examining MK-677 in the context of muscle wasting. This page synthesizes findings from peer-reviewed literature.
Research Summary
MK-677 was evaluated in Phase 2 trials for muscle wasting and sarcopenia. The oral GH secretagogue increases IGF-1 levels to those seen in young adults, which may support muscle protein synthesis. Studies in elderly populations showed increased fat-free mass with MK-677 treatment. The drug also improved nitrogen balance in calorie-restricted healthy volunteers, suggesting anti-catabolic effects. Despite promising Phase 2 results, clinical development was discontinued. MK-677 is not approved for muscle wasting or any other indication.
Referenced Studies
Click any PMID to view the full study on PubMed.
Other Peptides Studied for Muscle Wasting
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. MK-677 may have regulatory approval for some indications but should only be used under qualified medical supervision. Always consult a healthcare provider before making health decisions.